

PUBLICATIONS 2014-2015:

1. Lemp, N. A., Haga, K., Hacke, K., Treger, J. A., Bogan, B. T., Faure-Kumar, E., Logg, C. R., Kruse, C. A., Ciciarelli, J. C., **Kasahara, N.** Reduction of HLA class I expression by ribonucleic acid interference mitigates allogenicity of human primary and immortalized cells. *Clinical Transplants*, 2013: 93-101. (2014)
PMID: 25095496
2. Ciciarelli, J. C., **Kasahara, N.**, Lemp, N. A., Adamson, R., Dembitsky, W., Browne, B., Steinberg, S. Immunoglobulin G subclass analysis of HLA donor specific antibodies in heart and renal transplant recipients. *Clinical Transplants*, 2013: 413-422. (2014)
PMID: 25095537
3. Takahashi, M., Valdes, G., Hiraoka, K., Inagaki, A., Kamijima, S., Micewicz, E., Gruber, H. E., Robbins, J. M., Jolly, D. J., McBride, W. H., Iwamoto, K. S., **Kasahara, N.** Radiosensitization of gliomas by intracellular generation of 5-fluorouracil potentiates prodrug activator gene therapy with a retroviral replicating vector. *Cancer Gene Therapy*, 21 (10): 405-410. (2014)
PMID:25301172 / PMCID: PMC4246057
4. Lin, A. H., Timberlake, N., Logg, C. R., Liu, Y., Kamijima, S., Diago, O., Wong, K., Gammon, D. K., Ostertag, D., Hacke, K., Yang, E. C., Gruber, H., **Kasahara, N.**, Jolly, D. J. MicroRNA 142-3p Attenuates Spread of Replicating Retroviral Vector in Hematopoietic Lineage-Derived Cells While Maintaining an Antiviral Immune Response. *Human Gene Therapy*, 25 (8): 759-771. (2014)
PMID: 24825189 / PMCID:PMC4137335
5. Matsumoto, H., Haga, K., Ohno, I., Hiraoka, K., Kimura, T., Hermann, K., **Kasahara, N.**, Anton, P., McGowan, I. Mucosal gene therapy using a pseudotyped lentivirus vector encoding murine interleukin-10 (mIL-10) suppresses the development and relapse of experimental murine colitis. *BMC Gastroenterology*, Apr 8; 14:68. (2014)
PMID: 24712338 / PMCID:PMC3991919
6. Qin, Y., Fu, M., Takahashi, M., Iwanami, A., Kuga, D., Rao, R. G., Sudhakar, D., Huang, T., Kiyohara, M., Torres, K., Dillard, C., Inagaki, A., **Kasahara, N.**, Goodglick, L., Braun, J., Mischel, P. S., Gordon, L. K., Wadehra, M. Epithelial Membrane Protein-2 (EMP2) Activates Src and is a Novel Therapeutic Target for GBM. *Journal of Biological Chemistry*, 289 (20): 13974-13985. (2014)
PMID: 24644285 / PMCID:PMC4022868
7. Veena, M. S., Wilken, R., Zheng, J. Y., Gholkar, A., Venkatesan, N., Vira, D., Ahmed, S., Basak, S. K., Dalgard, C. L., Ravichandran, S., Batra, R. K., **Kasahara, N.**, Elashoff, D., Fishbein, M. C., Whitelegge, J. P., Torres, J. Z., Wang, M. B., Srivatsan, E. S. p16 Protein and gigaxonin are associated with the ubiquitination of NF κ B in cisplatin-induced senescence of cancer cells. *Journal of Biological Chemistry*, 289 (50): 34921-37. (2014)
PMID: 25331947 / PMCID: PMC4263890 [Available on 2015-12-12]
8. Mintz, P. J., Huang, K. W., Reebye, V., Nteliopoulos, G., Lai, H. S., Saetrom, P., **Kasahara, N.**, Jensen, S., Madhava, P., Gordon, M. Y., Marley, S. B., Behan, R., Spalding, D. R., Haoudi, A., Emara, M. M., Nicholls, J., Rossi, J. J., Habib, N. A. Exploiting human CD34+ stem cell-conditioned medium for tissue repair. *Molecular Therapy*, 22 (1): 149-159. (2014)
PMID: 23985698 / PMCID:PMC3978788
9. Reebye, V., Saetrom, P., Mintz, P. J., Huang, K. W., Swiderski, P., Peng, L., Liu, C., Liu, X., Lindkaer-Jensen, S., Zacharoulis, D., Kostomitsopoulos, N., **Kasahara, N.**, Nicholls, J. P., Jiao, L. R., Pai, M., Spalding, D. R., Mizandari, M., Chikovani, T., Emara, M. M., Haoudi, A., Tomalia, D. A., Rossi, J. J., Habib, N.A. Novel RNA oligonucleotide improves liver function and inhibits liver carcinogenesis in vivo. *Hepatology*, 59 (1): 216-227. (2014)
PMID: 23929703

10. Huang, T. T., Parab, S., Burnett, R., Diago, O., Ostertag, D., Hofman, F. M., Espinoza, F. L., Martin, B., Ibañez, C. E., **Kasahara, N.**, Gruber, H. E., Pertschuk, D., Jolly, D. J., Robbins, J. M. Intravenous Administration of Retroviral Replicating Vector, Toca 511, Demonstrates Therapeutic Efficacy in Orthotopic Immune-Competent Mouse Glioma Model. *Human Gene Therapy*, 26 (2): 82-93. (2015)
PMID: 25419577 / PMCID: PMC4326030 [Available on 2016-02-01]
11. Erickson, K. L., Hickey, M. J., Kato, Y., Malone, C. C., Owens, G. C., Prins, R. M., Liao, L. M., **Kasahara, N.**, Kruse, C. A. Radial Mobility and Cytotoxic Function of Retroviral Replicating Vector Transduced, Non-adherent Alloresponsive T Lymphocytes. *Journal of Visualized Experiments*, 2015 Feb 11; (96). (2015)
PMID: 25741775
12. Tseng, H. C., Inagaki, A., Bui, V. T., Cacalano, N., **Kasahara, N.**, Man, Y. G., Jewett, A. Differential Targeting of Stem Cells and Differentiated Glioblastomas by NK Cells. *Journal of Cancer*, 6(9): 866-876. (2015)
PMID: 26284138 / PMCID: PMC4532984
13. Iwabuchi, M., Narita, M., Uchiyama, T., Iwaya, S., Oiwa, E., Nishizawa, Y., Hashimoto, S., Bonehill, A., **Kasahara, N.**, Takizawa, J., Takahashi, M. Enhancement of the antigen-specific cytotoxic T lymphocyte-inducing ability in the PMDC11 leukemic plasmacytoid dendritic cell line via lentiviral vector-mediated transduction of the caTLR4 gene. *Molecular Medicine Reports*, 12(2): 2443-2450. (2015)
PMID: 25936433 / PMCID: PMC4464268
14. Yang, O. O., Ali, A., **Kasahara, N.**, Faure-Kumar, E., Bae, J. Y., Picker, L. J., Park, H. Short Conserved Sequences of HIV-1 Are Highly Immunogenic and Shift Immunodominance. *Journal of Virology*, 89 (2): 1195-1204. (2015)
PMID: 25378501 / PMCID: PMC4300636
15. Awe, J. P., Gschweng, E. H., Vega-Crespo, A., Voutila, J., Williamson, M. H., Truong, B., Kohn, D. B., **Kasahara, N.**, Byrne, J. A. Putative immunogenicity expression profiling using human pluripotent stem cells and derivatives. *Stem Cells Translational Medicine*, 4 (2): 136-145. (2015)
PMID: 25575527 / PMCID: PMC4303355 [Available on 2016-02-01]
16. Kubo, S., Takagi-Kimura, M., **Kasahara, N.** Combinatorial anti-angiogenic gene therapy in a human malignant mesothelioma model. *Oncology Reports*, 34(2): 633-638. (2015)
PMID: 26082103
17. Jotwani V, Shlipak MG, Scherzer R, Parekh RS, Kao WH, Bennett M, Cohen MH, Nowicki M, Sharma A, Young M, Tien PC, Parikh CR, Estrella MM. APOL1 Genotype and Glomerular and Tubular Kidney Injury in Women With HIV. *Am J Kidney Dis*. 2015 Jun;65(6):889-98.
18. Sciaranghella G, Wang C, Hu H, Anastos K, Merhi Z, Nowicki M, Stanczyk FZ, Greenblatt RM, Cohen M, Golub ET, Watts DH, Alter G, Young MA, Tsibris AM. CCR5 Expression Levels in HIV-Uninfected Women Receiving Hormonal Contraception. *J Infect Dis*. 2015 Nov 1;212(9):1397-401. PMID:
19. Jotwani V, Scherzer R, Abraham A, Estrella MM, Bennett M, Cohen MH, Nowicki M, Sharma A, Young M, Tien PC, Ix JH, Sarnak MJ, Parikh CR, Shlipak MG. Association of urine α 1-microglobulin with kidney function decline and mortality in HIV-infected women. *Clin J Am Soc Nephrol*. 2015 Jan 7;10(1):63-73.
20. Kiefer E, Hoover DR, Shi Q, Kuniholm MH, Augenbraun M, Cohen MH, Golub ET, Kaplan RC, Liu C, Nowicki M, Tien PC, Tracy RP, Anastos K. Association of markers of hemostasis with death in HIV-infected women. *J Acquir Immune Defic Syndr*. 2014 Nov 1;67(3):287-94.
21. Lang J, Scherzer R, Tien PC, Parikh CR, Anastos K, Estrella MM, Abraham AG, Sharma A, Cohen MH, Butch AW, Nowicki M, Grunfeld C, Shlipak MG. Serum albumin and kidney function decline in HIV-infected women. *Am J Kidney Dis*. 2014 Oct;64(4):584-91.

22. Peralta C, Scherzer R, Grunfeld C, Abraham A, Tien P, Devarajan P, Bennett M, Butch A, Anastos K, Cohen M, Nowicki M, Sharma A, Young M, Sarnak M, Parikh C, Shlipak M. Urinary biomarkers of kidney injury are associated with all-cause mortality in the Women's Interagency HIV Study (WIHS). *HIV Med.* 2014 May;15(5):291-300.
23. Jotwani V, Scherzer R, Abraham A, Estrella MM, Bennett M, Devarajan P, Anastos K, Cohen MH, Nowicki M, Sharma A, Young M, Tien PC, Grunfeld C, Parikh CR, Shlipak MG. Does HIV infection promote early kidney injury in women? *Antivir Ther.* 2014;19(1):79-87.
24. Koss, M.N. Handling and interpretation of the medical renal biopsy. *Methods in Molecular Biology*, 2014;1180:323-36. (2014)
25. Shigemitsu H., Orjioke N., Shriki J.E., Varras J., Koss M.N. A middle-aged man with cough, chest pain, and pulmonary artery filling defect: primary pulmonary artery sarcoma. *Chest*, 2014 Feb;145(2):407-10.
26. Myriam Foster, Jon-Patrick Allem, Nicole Mendez, Yasir Qazi, and Jennifer B. Unger. Evaluation of a telenovela designed to improve knowledge and behavioral intentions among Hispanic Patients with end-stage renal disease in Southern California. *Health & Ethnicity*, 2015

ABSTRACTS 2014-2015

1. Kamijima, S., Kimura, T., Inagaki, A., Hiraoka, K., Haga, K., Collins, S. A., Hermann, K. J., Hacke, K., Logg, C. R., Kao, C., Bochner, B. H., **Kasahara, N.**, Suzuki, H. Transcriptionally-Targeted Retroviral Replicating Vectors: A Novel Strategy for Gene Therapy of Prostate Cancer.(To be presented at the 35th Congress of the SociétéInternationale d'Urologie (SIU), Melbourne, Australia; October 15-18, 2015.)
2. Kubo, S., Takagi-Kimura, M., Logg, C. R., Hermann, K., **Kasahara, N.**Dual-vector prodrug activator gene therapy using two different retroviral replicating vectors. (XXIII Congress of the European Society of Gene & Cell Therapy, Helsinki, Finland; September 17-20, 2015.)
3. **Kasahara, N.**, Collins, S.A., Inagaki, A., Hiraoka, K., Ibañez, C., Robbins, J. M., Ostertag, D., Gruber, H. E., Skillings, J., Jolly, D. J. Retroviral Replicating Vectors for Gene Therapy of Cancer: Gene Therapy as Precision Medicine.(OMICS4thInternational Conference on Cell & Gene Therapy, London, UK; August 10, 2015; **selected for Keynote presentation**)
4. Inagaki, A., Hiraoka, K., Kamijima, S., Sato, M., Bogan, B., Logg, C. R., Gruber, H. E., Robbins, J. M., Lin, A., Jolly, D. J., **Kasahara, N.**Therapeutic efficacy of retroviral replicating vectors expressing thymidine kinase prodrug activator genes in experimental models of human glioma. (21st Annual Meeting of the Japan Society of Gene Therapy, Osaka, Japan; July 24-26, 2015; **selected for oral presentation**)
5. Kubo, S., Takagi-Kimura, M., **Kasahara N.** Combinational prodrug activator gene therapy using retroviral replicating vectors derived from amphotropic murine leukemia virus and gibbon ape leukemia virus. (21st Annual Meeting of the Japan Society of Gene Therapy, Osaka, Japan; July 24-26, 2015.)
6. Inoko, K., Hiraoka, K., Inagaki, A., Takano, H., Sato, S., Takahashi, M., Nakamura, T., Tsuchikawa, T., Shichinohe, T., Gruber, H., Jolly, D., **Kasahara, N.**, Hirano, S. Retroviral replicating vector (RRV)-mediated prodrug activator gene therapy for pancreatic cancer. (21st Annual Meeting of the Japan Society of Gene Therapy, Osaka, Japan; July 24-26, 2015; **selected for oral presentation**)
7. Collins, S. A., Logg, C. R., Inagaki, A., Kamijima, S., Lehouritis, P., Searle, P. F., Tangney, M.,**Kasahara, N.**Therapeutic efficacy of sequence-optimized nitroreductase for retroviral replicating vector (RRV) mediated prodrug activator gene therapy in experimental glioma. (9th International Conference on Oncolytic Viruses as Cancer Therapeutics, Boston, MA; June 13-16, 2015.)
8. Jolly, D. J., Ibanez, C., Robbins, J., Ostertag, D., Gruber, D., **Kasahara, N.**, Skillings, J. Replicating Retroviral Vectors as Therapeutic Agents: Update on Preclinical and Clinical Safety and Efficacy.(9th International Conference on Oncolytic Viruses as Cancer Therapeutics, Boston, MA; June 13-16, 2015; **selected for oral presentation**)
9. Kato, Y., Erickson, K., Haga, K., Malone, C., Inagaki, A., Kruse, C. A., **Kasahara, N.** RRV-Mediated Prodrug Activator Gene Therapy Combined with Alloreactive T Cell Immunotherapy for Malignancies in the CNS.(21st Annual Meeting of the International Society for Cellular Therapy, Las Vegas, NV; May 27-30, 2015.)
10. Hacke, K., Treger, J. A., Bogan, B. T., Rezek, V., Narukawa, M., Shimizu, S., Liu, P. Q., Reik, A., Lieber, A. M., Crooks, G. M., Kohn, D. B., An, D. S., Kitchen, S. G., Gregory, P. D., Cost, G. J., Holmes, M. C., **Kasahara, N.**A novel *in vivo*chemoselection strategy for genetically modified hematopoietic stem cells. (21st Annual Meeting of the International Society for Cellular Therapy, Las Vegas, NV; May 27-30, 2015.)
11. Inagaki, A., Hiraoka, K., Kamijima, S., Robbins, J. M., Jolly, D. J., Gruber, H. E., **Kasahara, N.** Preclinical Evaluation of Prodrug Activator Gene Therapy by Retroviral Replicating Vectors (RRV) in Experimental Models of Breast Cancer CNS Metastasis.(18th Annual Meeting of the American Society of Gene & Cell Therapy, New Orleans, LA;May 13-16, 2015.)
12. Collins, S. A., Logg, C. R., Inagaki, A., Kamijima, S., Lehouritis, P., Searle, P. F., Tangney, M., **Kasahara, N.**Sequence-Optimized Bacterial Nitroreductasefor Retroviral Replicating Vector (RRV)-Mediated Prodrug Activator Gene Therapy in Human Glioma Models. (18th Annual Meeting of the American Society of Gene & Cell Therapy, New Orleans, LA;May 13-16, 2015.)
13. Kubo, S., Takagi-Kimura, M., Logg, C. R., Hermann, K., **Kasahara, N.** Dual-vector prodrug activator gene therapy using retroviral replicating vectors derived from amphotropic murine leukemia virus and

gibbon ape leukemia virus. (18th Annual Meeting of the American Society of Gene & Cell Therapy, New Orleans, LA; May 13-16, 2015.)

14. Hacke, K., Treger, J. A., Bogan, B. T., Rezek, V., Narukawa, M., Shimizu, S., Liu, P. Q., Reik, A., Lieber, A. M., Crooks, G. M., Kohn, D. B., An, D. S., Kitchen, S. G., Gregory, P. D., Cost, G. J., Holmes, M. C., **Kasahara, N.** A Novel Method of Combined Preconditioning and *In Vivo* Chemoselection with 6-Thioguanine for Selection of Genetically Engineered Hematopoietic Stem Cells. (HIV Frontiers in Drug Development for Antiretroviral Therapies (DART) 2014 conference, Key Biscayne, FL; December 9-12, 2014, **selected for Outstanding Poster Award**)
15. Conway, A., Laganière, J., Paschon, D. E., Hacke, K., **Kasahara N.**, Gregory, P. D., Holmes, M. C., Cost, G. J. HPRT as a selectable safe harbor for transgenesis. (56th Annual Meeting of the American Society of Hematology, San Francisco, CA; December 6-9, 2014.)
16. Takahashi, M., Valdes, G., Inagaki, A., Kamijima, S., Hiraoka, K., Micewicz, E., McBride, W. H., Iwamoto, K. S., Herman, K., Collins, S., Tam, Q., Gruber, H. E., Robbins, J. M., Jolly, D. J., **Kasahara, N.** Enhanced therapeutic efficacy of prodrug activator gene therapy with a non-lytic retroviral replicating vector (Toca 511) combined with radiation therapy in experimental glioma. (19th Annual Meeting of the Society for Neuro-Oncology, Miami, FL, November 13-16, 2014; **selected for oral presentation**)
17. Collins, S. A., Logg, C. R., Inagaki, A., Kamijima, S., Lehouritis, P., Searle, P. F., Tangney, M., **Kasahara, N.** Retroviral Replicating Vector (RRV)-Mediated Prodrug Activator Gene Therapy With Codon-Optimized Nitroreductase in Experimental Glioma. (19th Annual Meeting of the Society for Neuro-Oncology, Miami, FL; November 13-16, 2014.)
18. Inagaki, A., Hiraoka, K., Kamijima, S., Robbins, J. M., Jolly, D. J., Gruber, H. E., **Kasahara, N.** Therapeutic efficacy of retroviral replicating vectors in human breast cancer CNS metastasis model. (19th Annual Meeting of the Society for Neuro-Oncology, Miami, FL; November 13-16, 2014.)
19. Ciciarelli, J. C., Lemp, N. A., Koss, M., Montes, R., Williams, B., **Kasahara, N.**, Naraghi, R., Shah, T. Assessment of the Luminex® Single Antigen and C1q assays' ability to correlate donor specific antibodies with kidney transplant rejection. (40th Annual Meeting of the American Society for Histocompatibility & Immunogenetics, Denver, CO; October 20-24, 2014; **selected for oral presentation**)
20. Ciciarelli, J. C., Koss, M., Shah, T., Lemp, N. A., **Kasahara, N.**, Naraghi, R. Donor specific antibody mean fluorescence intensities in positive, negative, and equivocal C4d renal transplants: Is equivocal C4d a time for treatment? (40th Annual Meeting of the American Society for Histocompatibility and Immunogenetics, Denver, CO; October 20-24, 2014.)
21. Lemp, N. A., Ciciarelli, J. C., **Kasahara, N.**, Koss, M., Vu, D., Naraghi, R., Shah, T. Graft rejection in a kidney transplant recipient with negative crossmatches and a single HLA-DP donor specific antibody. (40th Annual Meeting of the American Society for Histocompatibility and Immunogenetics, Denver, CO; October 20-24, 2014.)
22. Lemp, N. A., Musa, S., Chew, J., Garcia-Gomez, J., Senitzer, D., **Kasahara, N.**, Ciciarelli, J. C. A comparison of deceased donor typing strategies elicited by a novel HLA-DPB1 allele. (Late-Breaking Abstract; 40th Annual Meeting of the American Society for Histocompatibility and Immunogenetics, Denver, CO; October 20-24, 2014.)
23. Ciciarelli, J. C., Lemp, N. A., **Kasahara, N.**, Burns, K., Williams, B., Bloom, S., Montes, R., Pitpitan, B., Brown, B., Steinberg, S. Two kidney recipients with good function and donor specific antibodies positive for C1q and IgG4 subclass. (Late-Breaking Abstract; 40th Annual Meeting of the American Society for Histocompatibility & Immunogenetics, Denver, CO; October 20-24, 2014.)
24. Kato, Y., Erickson, K., Haga, K., Malone, C., Inagaki, A., Kruse, C. A., **Kasahara, N.** Adoptive T Cell Immunotherapy Using Alloreactive CTL Combined with RRV-Mediated Prodrug Activator Gene Therapy in Experimental Glioma. (20th Annual Meeting of the Japan Society of Gene Therapy, Tokyo, Japan, August 6-8, 2014; **selected for oral presentation**)
25. Inagaki, A., Hiraoka, K., Kamijima, S., Robbins, J. M., Jolly, D. J., Gruber, H. E., **Kasahara, N.** Therapeutic Efficacy of Retroviral Replicating Vectors in Breast Cancer Metastasis to the Brain. (20th Annual Meeting of the Japan Society of Gene Therapy, Tokyo, Japan; August 6-8, 2014; **selected for oral presentation**)

26. Kubo, S., Takagi-Kimura, M., Logg, C. R, **Kasahara, N.** Prodrug Activator Gene Therapy for Human Malignant Mesothelioma Using Replicating Gibbon Ape Leukemia Virus. (20th Annual Meeting of the Japan Society of Gene Therapy, Tokyo, Japan; August 6-8, 2014; **selected for oral presentation**)
27. Robbins, J. M., Huang, T. T., Jolly, D. J., **Kasahara, N.**, Aghi, M. K., Vogelbaum, M. A., Cloughesy, T. F., Chang, S. M., Kesari, S., Mikkelsen, T., Kalkanis, S. N., Landolfi, J. C., Elder, J. B., Chiocca, E. A., Gruber, H. E., Pertschuk, D. Ascending dose trials of a retroviral replicating vector (Toca 511) in patients with recurrent high-grade glioma. (50th Annual Meeting of American Society of Clinical Oncology (ASCO 2014), Chicago, IL; May 30-June 3, 2014.)
28. Hacke, K., Treger, J. A., Bogan, B. T., Rezek, V., Shimizu, S., Liu, P.-Q., Reik, A., Crooks, G. M., Kohn, D. B., An, D. S., Kitchen, S. G., Gregory, P. D., Cost, G. J., Holmes, M. C., **Kasahara, N.** Combined preconditioning and in vivo chemoselection with 6-thioguanine for selection of genetically modified hematopoietic stem cells. (17th Annual Meeting of the American Society of Gene & Cell Therapy, Washington DC; May 21-24, 2014; **selected for Outstanding Poster Award.**)
29. Timberlake, N., Lin, A., Hermann, K., Logg, C., Liu, Y., Kamijima, S., Diago, O., Wong, K., Anderson, C., Gammon, D., Yang, E., Gruber, H., Jolly, D. J., **Kasahara, N.** MicroRNA 142-3p Attenuates Spread of a Replicating Retroviral Vector in Hematopoietic-Lineage Derived Cells. (17th Annual Meeting of the American Society of Gene & Cell Therapy, Washington DC; May 21-24, 2014; **also selected for Outstanding Poster Award.**)
30. Jolly, D. J., Ibañez, C., Robbins, J. M., Ostertag, D., **Kasahara, N.**, Aghi, M. K., Vogelbaum, M. A., Bankiewicz, K., Cloughesy, T. F., Liau, L. M., Chang, S. M., Butowski, N., Kesari, S., Chen, C., Mikkelsen, T., Kalkanis, S. N., Landolfi, J. C., Bloomfield, S. M., Elder, J. B., Gruber, H. E., Pertschuk, D. Interim Report from Two Ongoing Ascending Dose Trials of a Retroviral Replicating Vector (Toca 511) in Patients with Recurrent High Grade Glioma. (17th Annual Meeting of the American Society of Gene & Cell Therapy, Washington DC; May 21-24, 2014; **selected for oral presentation**)
31. Huang, T., Parab, S., Diago, O., Lopez, F. E., Martin, B., Ibañez, C., **Kasahara, N.**, Gruber, H. E., Pertschuk, D., Jolly, D. J., Robbins, J. Toca 511 Intravenous Study in Humans Based on Uniform Distribution of Viral Spread Within the Tumor and Increased Survival in a Syngeneic, Orthotopic Mouse Glioma Model. (17th Annual Meeting of the American Society of Gene & Cell Therapy, Washington DC; May 21-24, 2014.)
32. Kubo, S., Takagi-Kimura, M., Logg, C. R, **Kasahara, N.** Highly Efficient Tumor Transduction and Antitumor Efficacy in Experimental Human Malignant Mesothelioma Using Replicating Gibbon Ape Leukemia Virus. (17th Annual Meeting of the American Society of Gene & Cell Therapy, Washington DC; May 21-24, 2014.)
33. Yumul, R., Richter, M., Giovani, M., **Kasahara, N.**, Lieber, A. Targeting tumor-associated macrophages for cancer therapy. (17th Annual Meeting of the American Society of Gene & Cell Therapy, Washington DC; May 21-24, 2014.)
34. **Chinchilla-Reyes, Tanglao, Koss, Nowicki.** Toward Uniform Nucleic Acid Testing Algorithm: Resolving Suspicious NAT Results for 3-Target Multiplexing Transcription Mediated Amplification (TMA) Assay. Oral (WTC 2014 – San Francisco, CA July 16th – 31st, 2014 selected for oral presentation)
35. **Chinchilla-Reyes, Tanglao, Koss, Nowicki.** Contemporary Prevalence of HIV, HBV, HCV Syphilis Among Organ, Tissue, Cornea and Reproductive Donors in the United States: Implications for NAT.
36. **Chinchilla-Reyes, Tanglao, Mone, Koss, Nowicki.** Screening for West Nile Virus in California: Resolving IgM Anti-WNV in the Area with Dengue Seroprevalence. (ATC 2015 – Philadelphia, PA May 2nd-6th, 2015)
37. **Cicciarelli, J. C., Chang, Y., Lemp, N. A., Koss, M., Shah, T., Montes, R., Williams, B., Kasahara, N., Min, D.I., Naraghi, R.** IgG Subclass Analysis in C4d+ DSA Positive Patients. (41st Annual Meeting of the American Society for Histocompatibility & Immunogenetics, Savannah, GA; September 28 - October 2, 2015; selected for oral presentation)
38. **Cho, Y., Cicciarelli, J.C., Lemp, N.A., Kasahara, N., Altrich, M.L.** HLA Class II Matching Effect on Kidney Transplantation. (41st Annual Meeting of the American Society for Histocompatibility & Immunogenetics, Savannah, GA; September 28 - October 2, 2015; selected for oral presentation)

39. **Vu D**, Shah T, Manzoor H, **Hutchinson I**, **Lemp NA**, Qazi YA, **Cicciarelli JC**, Naraghi R, **Min DI**. Genetic variations in a Sestrin2/Sestrin3/mTOR axis and development of new-onset diabetes after transplantation. (2014 World Transplant Congress, San Francisco, CA; July 26 - 31, 2014)
40. **Vu D**, Shah T, Manzoor H, **Hutchinson I**, **Lemp NA**, Qazi YA, **Cicciarelli JC**, Naraghi R, **Min DI**. Relationship between interleukin-2 polymorphism and BK virus infection after kidney transplantation. (2014 World Transplant Congress, San Francisco, CA; July 26 - 31, 2014)

